Zobrazeno 1 - 10 of 18 pro vyhledávání: '"Kohei, HANDA"'
1
Akademický článek
JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA‐4 and PD‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report
Autor: Masashi Kono, Yoriaki Komeda, Hisato Kawakami, Satoru Hagiwara, George Tribonias, Kohei Handa, Shunsuke Omoto, Mamoru Takenaka, Hiroshi Kashida, Naoko Tsuji, Masatoshi Kudo
Publikováno v: Cancer Reports, Vol 7, Iss 10, Pp n/a-n/a (2024)
ABSTRACT Background Immune checkpoint inhibitors have demonstrated efficacy against various cancers; however, there is a rising incidence of immune‐related colitis. Some cases of immune‐related colitis prove resistant to treatment, even with the
Externí odkaz: https://doaj.org/article/8ad359613d9940e38f8d3e929fdaf9b4
Zobrazit plný text záznamu
2
Akademický článek
Serum leucine‐rich alpha‐2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy‐naïve cases with ulcerative colitis
Autor: Masashi Kono, Yoriaki Komeda, George Tribonias, Saki Yoshida, Kenji Nomura, Kohei Handa, Tomoyuki Nagai, Satoru Hagiwara, Shunsuke Omoto, Mamoru Takenaka, Naoshi Nishida, Naoko Tsuji, Hiroshi Kashida, Masatoshi Kudo
Publikováno v: JGH Open, Vol 7, Iss 8, Pp 579-583 (2023)
Abstract Background and Aim Serum leucine‐rich alpha‐2 glycoprotein level has been reported to be a useful biomarker in assessing mucosal healing in patients undergoing biotherapy, where mucosal lesions caused by ulcerative colitis are difficult
Externí odkaz: https://doaj.org/article/38ca386887804f7ea46a536928e107da
Zobrazit plný text záznamu
3
Akademický článek
Real-World Data on Short-Term and Long-Term Treatment Results of Ustekinumab in Patients with Steroid-Resistant/Dependent Ulcerative Colitis
Autor: Yoriaki Komeda, George Tribonias, Masashi Kono, Kohei Handa, Shunsuke Omoto, Mamoru Takenaka, Satoru Hagiwara, Naoko Tsuji, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo
Publikováno v: Inflammatory Intestinal Diseases (2023)
Introduction: Ustekinumab is an IgG1 kappa monoclonal antibody directed against the common p40 subunit of interleukin-12 and interleukin-23, which activate Th1- and Th17-mediated immune responses, respectively. It has proven efficacy for the treatmen
Externí odkaz: https://doaj.org/article/5ecad67262324225b858391d8e01b08d
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje